1 The University of British Columbia, Vancouver, BC, Canada.
2 Providence Health Research Institute, Vancouver, BC, Canada.
Ann Pharmacother. 2019 Jul;53(7):665-674. doi: 10.1177/1060028019828420. Epub 2019 Feb 6.
Stroke prevention therapy decisions for patients with atrial fibrillation (AF) are complex and require trade-offs, but few validated patient decision aids (PDAs) are available to facilitate shared decision making.
To evaluate the effects of a novel PDA on decision-making parameters for AF patients choosing stroke prevention therapy.
We developed an evidence-based individualized online AF PDA for stroke prevention therapy and evaluated it in a prospective observational pilot study. The primary outcome was decisional conflict. Secondary outcomes were knowledge, usability/acceptability, patient preferences, effects on therapy choices, and participant feedback.
37 participants completed the PDA. The PDA could be completed independently and was well accepted. It significantly decreased the mean decisional conflict score ( P < 0.001) and all its subscales and increased participant AF knowledge ( P = 0.02). 76% of participants indicated that their individualized therapy attribute ranking was congruent with their values. The PDA-generated best-match therapy was chosen by 70% of participants in decision 1 (no therapy, aspirin, or oral anticoagulant), and 17% for decision 2 (choice of anticoagulant). Among AF patients, 60% chose a different drug than that currently prescribed to them. Conclusion and Relevance: Our PDA was effective for reducing decisional conflict, increasing patient knowledge, eliciting patients' values, and presenting therapy options that aligned with patients' values and preferences. Using the PDA revealed that many patients have therapy preferences different from their currently prescribed treatment. The PDA is a practical and potentially valuable tool to facilitate decision making about stroke prevention therapy for AF.
房颤(AF)患者的卒中预防治疗决策复杂,需要权衡利弊,但可用的经过验证的患者决策辅助工具(PDA)很少,难以促进共同决策。
评估一种新的 PDA 对选择卒中预防治疗的 AF 患者决策制定参数的影响。
我们开发了一种基于证据的个体化在线 AF PDA 用于卒中预防治疗,并在一项前瞻性观察性试点研究中对其进行了评估。主要结局是决策冲突。次要结局包括知识、可用性/可接受性、患者偏好、对治疗选择的影响以及参与者反馈。
37 名参与者完成了 PDA。PDA 可以独立完成且被很好地接受。它显著降低了平均决策冲突评分(P < 0.001)及其所有子量表,并提高了参与者的 AF 知识(P = 0.02)。76%的参与者表示他们的个体化治疗属性排名与他们的价值观一致。70%的参与者在决策 1(无治疗、阿司匹林或口服抗凝剂)中选择了 PDA 生成的最佳匹配治疗,17%的参与者在决策 2(抗凝剂选择)中选择了最佳匹配治疗。在 AF 患者中,60%的人选择了与目前处方不同的药物。结论和相关性:我们的 PDA 有效降低了决策冲突,增加了患者的知识,引出了患者的价值观,并提供了与患者的价值观和偏好相符的治疗方案。使用 PDA 发现,许多患者的治疗偏好与他们目前的处方治疗不同。PDA 是促进 AF 卒中预防治疗决策的实用且有潜在价值的工具。